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Gastric  cancer  is a common  disease  with  limited  treatment  options  and  a poor  prognosis.  Many  gas-
tric cancers  harbour  potentially  actionable  targets,  including  over-expression  and  mutations  in tyrosine
kinase  pathways.  Agents  have  been  developed  against  these  targets  with  varying  success-  in  particular,
the use  of  trastuzumab  in  HER2-overexpressing  gastric  cancers  has  resulted  in overall  survival  beneﬁts.
Gastric  cancers  also  have high  levels  of  somatic  mutations,  making  them  candidates  for  immunother-astric cancer
olecular classiﬁcation
argeted therapy
mmunotherapy
apy;  early  work  in  this  ﬁeld  has  been  promising.  Recent  advances  in  whole  genome  and  multi-platform
sequencing  have  driven  the  development  of  molecular  classiﬁcation  systems,  which  may  in turn  guide
the  selection  of  patients  for targeted  treatment.  Moving  forward,  challenges  will  include  the develop-
ment  of  appropriate  biomarkers  to predict  responses  to targeted  therapy,  and  the  application  of  new
molecular  classiﬁcations  into  trial development  and  clinical  practice.
© 2016  The  Authors.  Published  by Elsevier  Ireland  Ltd.  This  is an open  access  article  under  the CC. Introduction
Gastric cancer is the ﬁfth most common cancer worldwide, and
ne of the leading causes of cancer-related mortality (International
gency for Research on Cancer, 2014). The treatment options for
astric cancer are limited, and patients invariably have a poor
rognosis- patients with Stage 3 and 4 gastric cancer have 5 year
∗ Corresponding author at: Duke-NUS Graduate Medical School, 8 College Road,
69857, Singapore.
E-mail address: gmstanp@duke-nus.edu.sg (P. Tan).
ttp://dx.doi.org/10.1016/j.critrevonc.2016.02.007
040-8428/© 2016 The Authors. Published by Elsevier Ireland Ltd. T
http://creativecommons.org/licenses/by-nc-nd/4.0/).BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
overall survival rates of 9.2–19.8% and 4.0% respectively (National
Cancer Institute, 2014). Despite recent breakthroughs in the use of
targeted therapy in many other cancers, similar advances in gastric
cancer have been slower. Part of the challenge arises from the het-
erogeneity of gastric cancers on a clinical, histologic and molecular
level, which demands an individualized approach (Tan, 2015).
Historically, gastric cancer has been subdivided by histologic
subtype via the World Health Organisation (WHO) or Lauren clas-
siﬁcations, each with distinct clinical and epidemiologic features.
The Lauren classiﬁcation divides gastric cancers into intestinal and
diffuse types, accounting for 54% and 32% respectively (Polkowski
et al., 1999). Intestinal gastric cancers tend to be associated with
his is an open access article under the CC BY-NC-ND license
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nvironmental factors like Helicobacter pylori infection, occur in
he antrum, and are often preceded by intestinal metaplasia. Diffuse
astric cancers on the other hand are more poorly differentiated,
ccur in younger patients, have a poorer prognosis and are found
n inherited conditions. The WHO  classiﬁcation splits gastric can-
ers by their resemblance to metaplastic intestinal tissue (Dicken
t al., 2005; Hu et al., 2012). More recently, the genomic study and
haracterisation of gastric tumours have given further insight into
he pathogenesis of these cancers, and identiﬁed new potential
herapeutic targets. This may  pave the way for the development
f personalised prognostication and treatment.
. Molecular classiﬁcation
The increasing efﬁcacy and accessibility of sequencing has
llowed multi-platform sequencing in large numbers, and in turn
rives the development of classiﬁcation systems based not on
istopathology but on molecular features. The landmark Cancer
enome Atlas (TCGA) study performed sequencing of 295 gas-
ric cancer samples on 6 different molecular platforms. Based on
his, gastric cancer was clustered into 4 groups- Ebstein-Barr virus
EBV) positive (9%), tumours with microsatellite instability (MSI)
22%), genomically stable tumours (20%) and those with chromoso-
al  instability (50%) (The Cancer Genome Atlas Research Network,
014).
The EBV positive subtype, interestingly, showed a high level
f non-silent PIK3CA mutations (80%), of which 68% were recur-
ent, as well as mutations in ARID1A (54%) and BCOR (23%). The
ate of PIK3CA mutations in the other subtypes was 3–42%. There
as also a high prevalence of DNA hypermethylation, particularly
f the CDKN2A promoter, and ampliﬁcation of the genes encod-
ng immune checkpoint ligands PD-L1 and PD-L2. The MSI  high
ubgroup, characterised by high levels of microsatellite instabil-
ty without major chromosomal abnormalities, were enriched in
umours with hypermethylation, especially of the MLH1 promoter,
eading to MLH1 silencing. The chromosomal instability subtype
as associated with extensive somatic copy-number aberrations,
nd ampliﬁcations in genes involved in the RTK (receptor tyrosine
inase)-RAS pathway that lead to its activation. Finally, the genom-
cally stable subtype, which lacked either chromosomal alterations
r microsatellite instability, was high in CDH1 and RHOA mutations.
These molecular analyses showed that each of the various sub-
ypes had certain candidate therapeutic targets. The presence of
IK3CA mutations in EBV positive tumours suggest that these
umours may  be particularly amenable to PI3K inhibitors. It was
oted that the PIK3CA mutations that occurred in EBV positive gas-
ric cancers were scattered over the gene, rather than concentrated
ver the kinase and helicase domains in exons 9 and 20, as was seen
n the other subtypes. It remains to be seen whether these PIK3CA
utations truly have functional signiﬁcance on the PI3K pathway.
n addition, with new strides being made in immunotherapy, the
revalence of PD-L1 and PD-L2 over-expression in EBV positive
umours may  also be of interest. In the genomically stable subtype,
HOA and CLDN18 gene products are potential therapeutic targets,
hile in the chromosomal instability subtype, VEGF and other RTK
mpliﬁcations highlight the possible role for RTK inhibitors like
amucirumab. MSI  cases generally lacked targetable ampliﬁcations,
lthough mutations in PIK3CA, ERBB2, ERBB3, EGFR and ARID1A were
ccasionally seen.
A similar undertaking by the Asian Cancer Research Group
ACRG) looked at 300 primary tumours, on which gene expression
roﬁling, genome-wide copy number microarrays and targeted
ene sequencing were done (Cristescu et al., 2015). In this study,
astric cancer was divided into 4 groups- MSS/EMT (microsatellite
table/epithelial-to-mesenchymal transition), which encompassedgy/Hematology 100 (2016) 141–146
the outliers on the EMT  distribution, MSI, MSS/TP53+, which had
patients with intact TP53 activity, and MSS/TP53-, tumours which
had functional loss of TP53. This population was unique in that
long term follow up data was  available. On a clinical level, these
subtypes had prognostic value- with best prognosis in the MSI  sub-
type, then MSS/TP53+, MSS/TP53- and then MSS/EMT. MSI tumours
were more likely to be intestinal and diagnosed at an early stage,
while MSS/EMT tumours were diffuse and more likely to recur.
On a molecular level, the MSI  subtype was conﬁrmed to have
hypermutation. Ampliﬁcations of ERBB2,  CCNE1 and CCND1 tended
toward mutual exclusivity in the MSS/TP53- subtype, which can be
targeted by trastuzumab, CDK2 inhibitors and CDK4/6 inhibitors
respectively. The MSS/TP53+ subtype showed a higher prevalence
of mutations in APC, ARID1A, KRAS, PIK3CA and SMAD 4. In particular,
sequencing revealed that of the 3 most common PIK3CA mutations,
the ones in the MSI  subtype tended to be H1047R mutations (A- > T),
while in MSS  tumours, E542 K and E545K mutations (G- > A) pre-
vailed. These mutant PIK3CA proteins have been shown to cause
oncogenic transformation in vitro, but it is not known yet which
ones are more susceptible to PI3K inhibitors (Kang et al., 2005).
New genetic alterations and associations with particular tumour
types continue to be identiﬁed, and contribute to our understand-
ing of gastric cancer. For instance, RHOA hotspot mutations have
been found to be common in diffuse (14.3%) but not intestinal-type
tumours, with suggestions of a role as a driver of tumorigenesis.
Other possible drivers that have recently been identiﬁed include
MUC6, which codes for a mucoprotective mucin, RNF43,  which neg-
atively regulates WNT  signalling, CTNNA2, involved in cell adhesion,
and GLI3 and ZIC4, both of which are involved in sonic hedgehog
signalling (Wang et al., 2014). Recently, 5 recurrent fusion genes
have been identiﬁed- one of them, CLDN18-ARHGAP 26,  is seen in
3% of Asian Gastric cancers and is thought to contribute to the
invasiveness of tumour cells (Yao et al., 2015).
These studies suggest that we  should be moving towards molec-
ular screening and classiﬁcation of gastric cancers, to stratify them
for treatment and prognostic purposes. Despite this, we are still
some way  from a consensus on the most relevant system.
3. Tyrosine kinase targets
Many of the promising molecular targets in gastric cancer are
receptor tyrosine kinases (RTKs). Deng et al. proﬁled copy num-
ber alterations in gastric cancers and found that at least 37% of
them harboured genomic alterations in RTKs that may  be targets
for agents that are currently available or under development. These
included 9% of tumours with FGFR2 alterations, 9% KRAS, 8% EGFR,
7% HER2 and 4% MET  (Deng et al., 2015).
3.1. HER2
HER2 is a transmembrane tyrosine kinase and a member of the
epidermal growth factor receptor (EGFR) family, involved in the
regulation of cell proliferation, adhesion, migration and differen-
tiation. This occurs via heterodimerization with other members of
the HER family, leading to activation of the RAS-MAPK and PI3K-
AKT pathways. The HER2 gene is located on chromosome 17q21
(Gravalos and Jimeno, 2008; Hudis, 2007). HER2 overexpression
occurs in 15–30% of gastric cancers, and prevalence depends on
the histology and location of the tumour- it is more common in
the intestinal type (34% intestinal, 6% diffuse, 20% mixed) and in
gastro-oesophageal junction tumours (32% in GEJ  tumours vs 18%
in gastric cancers) (Bang et al., 2010). HER2 positivity can be deﬁned
by protein expression on immunohistochemistry, and is obtained
when there is strong membranous reactivity in >/ = 10% of cancer
cells on surgical specimens or a cluster of ﬁve or more cells with
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kinase inhibitor geﬁnitib showed some response in gastro-
oesophageal junction tumours (overall response rate 9%), there wasY.L.E. Ang et al. / Critical Reviews in O
trong reactivity on a biopsy specimen. It can also be identiﬁed on
uorescence in-situ hybridisation (FISH), with a HER2:CEP17 ratio
f >/ = 2 considered positive.
HER2 positive gastric cancers have been successfully targeted
y the anti-HER2 monoclonal antibody trastuzumab, which works
hrough inihibition of the MAPK and PI3K/Akt pathways to sup-
ress cell growth and proliferation, as well as via the recruitment of
mmune effector cells responsible for antibody-dependent cellular
ytotoxicity (ADCC). The Phase III ToGA study looked at the role of
dding trastuzumab to chemotherapy in the ﬁrst line of treatment
n patients with HER2 positive advanced gastric cancer. Patients
ere randomised to ﬂuorouracil based chemotherapy and cisplatin
ith or without trastuzumab. There was an overall survival beneﬁt
rom the addition of trastuzumab- median overall survival (OS) 13.8
s 11.1 months (HR 0.74, CI 0.60–0.91; p = 0.0046), with no increase
n the rates of grade 3 or 4 adverse events (Bang et al., 2010). The
bjective response rate was also higher with trastuzumab, at 47%
s 35% in the standard arm. In the ToGA population, there was a
roportion of patients (22%) who were FISH positive but IHC 0–1-
hese patients did not seem to beneﬁt from trastuzumab. Based
n the ACRG and TCGA classiﬁcations, HER2 ampliﬁcation may  be
ound more in the MSS/TP53- and in the chromosomal instability
ubgroups respectively.
Other anti-HER2 agents have been studied in the treatment of
ER2 positive advanced gastric cancer. Lapatinib, a dual anti-EGFR
nd anti-HER2 tyrosine kinase inhibitor has been investigated. In
he TRIO-013/LOGIC trial, patients with advanced or metastatic
ER2 positive gastric cancer were randomised to capecitabine and
xaliplatin with lapatinib or placebo. The primary endpoint of over-
ll survival beneﬁt was not reached, with a median OS of 12.2
onths in the lapatinib group and 10.5 months in the placebo
roup (HR 0.91, 95% CI 0.73–1.12, p = 0.35). Progression free sur-
ival (PFS) was  also not signiﬁcantly improved- median PFS 6.0 vs
.4 months (HR 0.86, 95% CI 0.71–1.04, p = 0.10) (Hecht et al., 2013).
n the second line setting, the Tytan trial compared paclitaxel alone
ith lapatinib plus paclitaxel, and again did not reveal signiﬁcant
eneﬁts in median OS, PFS or time to progression (TTP) (Satoh et al.,
014). Recently, pertuzumab, a monoclonal antibody that binds the
xtracellular dimerization domain of HER2 preventing its dimeriza-
ion, has shown beneﬁts in the treatment of breast cancer. There is
urrently a Phase III trial, the JACOB trial, underway to at the efﬁcacy
f pertuzumab in combination with trastuzumab and chemother-
py (cisplatin plus a ﬂuoropyrimidine) (NCT01774786). Another
hase III trial is looking at trastuzumab emtansine, an antibody-
rug conjugate, compared to a taxane in patients with previously
reated advanced HER2 positive gastric cancer (NCT01641939).
.2. VEGF
Vascular endothelial growth factor (VEGF) overexpression is a
ommon feature in gastric cancers, seen in up to 58% of cases (Oh
t al., 2008). In the TCGA paper, recurrent ampliﬁcation of the gene
ncoding ligand VEGF-A was particularly seen in chromosomal
nstability tumours, and in 7% of tumours overall. It promotes car-
inogenesis by inducing angiogenesis and neovascularisation, and
he VEFGR signalling pathway is therefore an important therapeutic
arget.
The human IgG1 monoclonal antibody VEGFR2 antagonist
amucirumab has been established as part of the standard of care in
he second line treatment of metastatic gastric cancer. The REGARD
tudy was a Phase III trial which compared ramucirumab with best
upportive care in second line advanced gastric cancer, and showed
n overall survival beneﬁt of 1.4 months (5.2 vs 3.8 months, HR
.776, 95% CI 0.603–0.998, p = 0.047) (Fuchs et al., 2014). The Phase
II RAINBOW study compared the use of ramucirumab vs placebo,
n combination with paclitaxel, in patients with advanced gastricgy/Hematology 100 (2016) 141–146 143
cancer that had progressed on ﬁrst line chemotherapy of ﬂuoropy-
rimidine/platinum with or without an anthracycline (Wilke et al.,
2014). There was a statistically signiﬁcant overall survival bene-
ﬁt with ramucirumab of 9.6 months vs 7.4 months (HR 0.807, 95%
CI 0.678–0.962, p = 0.017), with an increase of 1 year OS from 30%
to 40%. Progression free survival, objective response rates (ORR)
and disease control rates (DCR) were also improved. However, on
subset analyses, the overall survival beneﬁt of ramucirumab was
not seen in Asian patients. The RAINFALL trial is in the process of
looking at ramucirumab in combination with capecitabine and cis-
platin in the ﬁrst line therapy in patients with metastatic gastric
cancer (NCT02314117). Bevacizumab, a VEGF directed monoclonal
antibody, has also been studied, with less promising results. In the
AVAGAST study, cisplatin and capecitabine were given with beva-
cizumab or placebo. There was  no overall survival beneﬁt from the
addition of bevacizumab- median OS 12.1 months vs 10.1 months
(HR 0.87, 95% CI 0.73–1.03, p = 0.1002), although PFS and ORR were
improved (Ohtsu et al., 2011).
It is worth noting that the level of VEGF overexpression has
not been conclusively shown to correlate with the beneﬁts derived
from VEGF pathway inhibitors. In the AVAGAST trial, patients with
high plasma VEGF-A levels showed improved overall survival com-
pared to those with low VEGF-A levels. Currently, ramucirumab is
approved for use in second line gastric cancers, but the identiﬁca-
tion of a biomarker predicting response to anti-VEGF agents would
allow us to better select appropriate patients for anti-angiogenic
treatment.
3.3. EGFR
Overexpression of EGFR occurs in 2.3–40% of gastric tumours,
and has been associated with poorer survival. Based on this, and
given the success of both tyrosine kinase inhibitors and anti-EGFR
monoclonal antibodies in other tumour types such as colorectal and
lung cancer, studies have been done to investigate the beneﬁts in
gastric cancer (Dragovich and Campen, 2009).
So far, results have been disappointing. The EXPAND trial was a
randomised phase III trial that evaluated the addition of cetuximab
to the standard capecitabine and cisplatin in ﬁrst line advanced
gastric cancer. The study did not meet its primary endpoint of PFS
improvement (HR 1.09, 95% CI 0.92–1.29, p = 0.32), with higher
rates of toxicity. EGFR expression was  generally low, with a median
IHC score of zero, and there was  no signiﬁcant difference between
treatment groups according to EGFR score (Lordick et al., 2013). In
a similar patient group, the Phase III REAL3 study gave epirubicin,
oxaliplatin and capecitabine with or without panitumumab, and in
fact found a signiﬁcant reduction in median overall survival with
the addition of panitumumb (11.3 months vs 8.8 months, HR 1.37,
95% CI 1.07–1.76, p = 0.013). This study incorporated an exploratory
biomarker analysis- in the 10 patients who had KRAS mutations,
there was  a non-signiﬁcant trend towards beneﬁt from the addi-
tion of panitumumab: OS HR 0.23 (95% CI 0.05–1.15) (Waddell et al.,
2013). These studies highlight the fact that preselecting patients
based on biomarkers may  be the way  forward in running trials of
targeted agents.
A Phase III trial looking at nimotuzumab in combination
with irinotecan as second line treatment is currently underway
(NCT01813253). Likewise, while the small molecular tyrosineno response seen in the gastric cancers. No somatic EGFR mutations
were found, and EGFR overexpression and Akt expression were not
found to be predictive of response to geﬁnitib (Dragovich et al.,
2006).
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.4. FGFR2
The ﬁbroblast growth factor type 2 (FGFR2) gene located on chro-
osome 10q26 encodes the FGFR2 tyrosine kinase, which regulates
ell proliferation and angiogenesis via activation of the MAPK, PI3K,
TAT and phospholipase Cy signalling pathways. FGFR2 ampliﬁca-
ion has been shown in various studies to occur in 3–16% of gastric
ancers. It tends to be associated with diffuse type gastric cancers,
ater stage and poorer prognosis (Inokuchi et al., 2015).
Drugs targeting FGFR receptors have shown promise in pre-
linical studies as well as early clinical trials. One of the agents
eing actively studied is dovitinib (TKI258), a multikinase inhibitor
gainst FGFR, VEGFR, PDGFR, FLT-3 (FMS-like tyrosine kinase 3),
IT and colony stimulating factor 1. Deng et al. tested the activity
f dovitinib in FGFR2-ampliﬁed and non-ampliﬁed gastric cancer
ell lines, and found that dovinitib decreased phosphorylation of
GFR2, ERK and AKT. There was potent growth inhibitory activ-
ty and reduction in colony formation in the ampliﬁed KATO III
nd SNU-16 cell lines but not in the non-ampliﬁed cell lines.
ovinitib also reduced mean tumour size in an FGFR2-ampliﬁed
uman gastric cancer xenograft model (Deng et al., 2015). There
re currently a few clinical trials underway evaluating the use
f dovitinib in advanced FGFR2-ampliﬁed gastric CA, including a
hase II trial of dovitinib monotherapy after failure of 2 lines of
hemotherapy (NCT01719549), and a Phase I–II trial combining
ocetaxel with dovitinib after the failure of 1 line of chemother-
py (NCT01921673). The results of the SHINE trial, which looked
t another FGFR2 inhibitor AZD4547 versus paclitaxel in advanced
astric cancer with FGFR2 ampliﬁcation, were recently reported. 9%
f patients screened had FGFR2 ampliﬁcation. The overall median
FS on the AZD4547 arm was 1.8 months, compared to 3.5 months
or paclitaxel, and in the 9% of patients with FGFR amplication, PFS
as 1.5 months and 2.3 months respectively (NCT01457846) (Bang
t al., 2015)
.5. PI3K pathway
The PI3K-AKT-mTOR pathway is another frequently altered
athway in gastric cancer, either through activating mutations
f PIK3CA, loss of the negative regulator PTEN, or ampliﬁcation
f AKT. Activation of this pathway can increase cell proliferation
y promoting transcriptional activity, decreasing apoptosis and
ncreasing cytoskeleton dynamics. The overall rate of PIK3CA muta-
ions has differed greatly between studies, from just 0.8% to 20%
verall in the TCGA study. This pathway can be targeted at the level
f PI3K or downstream at AKT or mTOR.
Various PI3K inhibitors have been studied in gastric cancer, so far
ithout deﬁnitive clinical results. Inhibitors like LY294002, BEZ 235
nd BKM120 have been shown to have effect in preclinical studies
Xie et al., 2013; Mueller et al., 2012). Clinical trials are currently
nderway, often with PI3K inhibitors in combination with other
rugs, including BYL719 together with HSP90 inhibitor AUY 922
n gastric cancer, and BKM120 with hedgehog pathway inhibitor
DE 225 in advanced solid tumours (NCT01613950, NCT01576666).
he AKT inhibitor AZD5363 is being tested in the second line,
n combination with paclitaxel in gastric cancer patients with
nd without PIK3CA mutations or ampliﬁcations (NCT02451956,
CT02449655). Another AKT inhibitor, GDC-0068, has been studied
n the Phase II JAGUAR trial, in which patients with inoperable gas-
ric or gastroesophageal junction adenocarcinomas are randomised
o modiﬁed FOLFOX with or without GDC-0068. Results of this trial
re awaited. (NCT01896531).mTOR inhibitors have shown marked activity in other solid
umours, such as in renal cell carcinoma and breast cancer. In gas-
ric cancer, a phase II study of everolimus had promising results,
ith a disease control rate of 54.7%, a median PFS of 2.7 monthsgy/Hematology 100 (2016) 141–146
and a median OS of 10.1 months (Doi et al., 2010). This lead to
the GRANITE-1 study, which evaluated everolimus vs placebo in
patients with advanced gastric cancer that had progressed after
one or two  lines of systemic chemotherapy. However, everolimus
did not show an overall survival beneﬁt (5.4 months vs 4.3 months,
HR 0.90, 95% CI 0.75–1.08, p = 0.124), although there was improve-
ment in median PFS (1.7 months vs 1.4 months, HR 0.66, 95% CI
0.56–0.78) (Ohtsu et al., 2013). Biomarker analyses of GRANITE-1
are ongoing, as the identiﬁcation of biomarkers may help deﬁne the
patients who would beneﬁt most from everolimus.
3.6. MET
MET ampliﬁcation or overexpression has been found in 0–23%
of gastric cancers on immunohistochemistry and in-situ hybridi-
sation, representing a small but signiﬁcant proportion of gastric
cancers that may  be amenable to targeting by MET  inhibitors
(Lee et al., 2012). AMG-337 is a c-MET inhibitor in the early
phases of development that has shown promising results in gas-
tric cancer- in the ﬁrst-in-man Phase I trial, 8 patients with MET
ampliﬁcation were included (out of 45 in total)- 7 of these had
gastro-oesophageal cancer, with 1 complete response that has
lasted >3years, 4 partial responses and 1 stable disease (Hong et al.,
2014). However, the phase II study of AMG337 has been halted
since last year due to disappointing results. A phase II study is
currently underway (NCT02016534). Two larger phase III trials in
gastric cancer, for the c-MET inhibitors rilotumumab (an antibody
against c-MET ligand hepatocyte growth factor) and onartuzumab
(an antibody against the extracellular domain of c-MET) have been
halted- in the case of rilotumumab, there was  an increase in the
risk of death from the study drug (Cunningham et al., 2013).
The disparate results between AMG-337 and rilotu-
mumab/onartuzumab could be due to biomarker selection. In
MetGastric, which evaluated the addition of onartuzumab to
mFOLFOX6, and in RILOMET-1, which looked at the addition of
rilotumumab to epirubicin, cisplatin and capecitabine, MET  status
was determined by IHC, and patients with 2+ or 3+ were included
(NCT01662869). However, in the AMG337 studies, MET  status
was determined by ﬂuorescence in situ hybridisation or next
generation sequencing- this more accurate detection method may
explain the stark responses seen. Other possibilities would include
issues with the dose intensities of rilotumumab/onartuzumab-
perhaps the combination with chemotherapy and its accompa-
nying toxicities limits the optimisation of MET  inhibitor dosage
(Table 1).
4. Immunotherapy
Gastric tumorigenesis depends not only on mutations within the
tumour cell itself, but also with its interaction with the surrounding
immune environment (Hanahan and Weinberg, 2011). The ability
of a tumour cell to escape immune detection and removal involves
the programmed cell death protein-1/programmed death-ligand
1 (PD-1/PD-L1) pathway, as well as the interaction of CTLA4 with
its ligands. When PD-L1 binds to its receptor on T lymphocytes,
it inhibits T lymphocyte proliferation and induces apoptosis of
tumour speciﬁc T cells, reducing the cytotoxic immune response
towards the tumour. The TCGA study showed that EBV positive gas-
tric cancers in particular over-expressed PD-L1 and PD-L2, which
suggests that these tumours would be particularly susceptible to
anti-PD1 therapy.
This was  seen in the Keynote 012 trial, which was a Phase 1b
study of anti-PD-1 IgG antibody pembrolizumab in patients with
advanced solid tumours that stained positive for PD-L1 on immuno-
histochemistry, including a cohort of gastric cancer patients. 40% of
patients screened were PD-L1 positive, and 67% had received >/ = 2
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prior therapies. Overall response rate was  22% by central review,
and median response duration was 24 weeks, with a 6 month PFS
rate of 24% and a 6 month OS rate of 69% (NCT01848834) (Muro
et al., 2015). Nivolumab, another anti-PD1 antibody, is being tested
in a Phase III trial in previously treated gastric cancer, which will
not limit enrollment by PD-L1 biomarker status (NCT02267343).
In addition, dual blockage of PD-1 and CTLA-4 is being evaluated,
including in a phase Ib/II trial of nivolumab and nivolumab plus ipil-
imumab which is enrolling patients with metastatic gastric cancer
(NCT01928394). MEDI4736, a human IgG1 monoclonal antibody
against PD-L1, has also shown clinical activity in Phase I, as well as
in early results from the expansion cohort, which includes patients
with gastro-oesophageal cancers (Lutzky et al., 2014; Segal et al.,
2014).
A recent study has shed light on the beneﬁts of anti-PD-1
agent pembrolizumab in patients with mismatch repair deﬁ-
cient tumours, based on the hypothesis that these tumours have
more somatic mutations and therefore may  be more susceptible to
immune checkpoint blockade. This study looked at pembrolizumab
in heavily treated patients in three cohorts, and found that the
beneﬁts of pembrolizumab were most marked in patients with
MMR  deﬁcient cancers. In the MMR  deﬁcient non-colorectal
cohort, which included gastric cancer patients, immune PFS at 20
weeks was seen in 67% of patients, with a 71% immune overall
response rate. The median PFS was 5.4 months and the median
OS was not reached. This suggests that cancers with higher levels
of somatic mutations have a higher response rate to PD-1/PD-L1
inhibition (Le et al., 2015). Of the various tumour types, gastric
cancer has one of the highest levels of somatic mutations, trailing
only melanoma, lung and bladder cancers (Lawrence et al., 2013).
The role of immunotherapy in melanoma and lung cancers is
already ﬁrmly established, and emerging information points to
gastric cancer as the next frontier.
5. Conclusion
Our understanding of the genomics of gastric cancer has
expanded signiﬁcantly over the last few years. Sequencing
advances have yielded many potentially targetable mutations,
which in turn have led to the emergence of new therapies against
these targets. Gastric cancer is a disease with a poor prognosis and
limited treatment options, and these developments have given us
new hope in improving patients’ survival.
The most successful example of targeted therapy has been the
use of trastuzumab, which has now been established as the stan-
dard of care in HER2 positive disease. In addition, exciting strides
are being made in immunotherapy. Gastric cancer is striking in its
high levels of somatic mutations, making it an ideal candidate for
PD-1/PD-L1 blockade. It will be interesting to see how immunother-
apy and other targeted therapies make advances beyond the later
lines of treatment in advanced cancers, into the ﬁrst line and even
adjuvant settings.
Moving forward, there are still many challenges ahead. Firstly,
although sequencing reveals druggable targets, not all of these have
been successful in clinical testing. This is likely due to the fact that
gastric cancers are genomically complex tumours, and not all muta-
tions play the role of driver mutations. Targeted therapy may  also
be limited by the tumour heterogeneity seen in gastric cancers, and
the existence of redundancy in the multiple pathways of carcino-
genesis. Further work is needed to understand the central processes
governing gastric cancer development, either to identify shared
pathways for targeting, or if none, to better select personalised
treatment.
Secondly, there is the need to identify appropriate biomark-
ers to select patients for treatment with targeted agents. Current
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pathway increases the chemosensitivity of gastric cancer to vincristine? Oncol.
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iomarker testing in trials tends to focus on one or two  speciﬁc
iomarkers, often using protein expression rather than genetic test-
ng. Whole genome sequencing (WGS) is set to play an important
ole in this area, as it would allow us to widen the search for
iomarkers in clinical trials of new therapeutic agents. In future,
f more targeted agents emerge and biomarkers for their efﬁcacy
re recognised, sequencing to individualize treatment may  become
art of routine practice. WGS  may  also give us further insight into
umour heterogeneity. The focus now is on translating the diag-
ostic potential of this method into clinical practice, in particular
n developing the expertise to deal with the large amounts of infor-
ation yielded by WGS.
Finally, the development of molecular classiﬁcation systems has
alled into discussion how and when to best apply them. One of
he potential uses is in recruitment for trials- each subgroup is
nriched with particular mutations and can be used to identify suit-
ble patients. In the clinical setting, we need to establish stronger
orrelations between histological or clinical features with molec-
lar features. If this can be done, classiﬁcations may  be useful in
rognostication and also in guiding our targeted molecular testing.
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